Last reviewed · How we verify
RC48-ADC in Combination with gemcitabine
At a glance
| Generic name | RC48-ADC in Combination with gemcitabine |
|---|---|
| Sponsor | RemeGen Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 (PHASE3)
- RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure (PHASE2, PHASE3)
- A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer (PHASE2)
- A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma (PHASE3)
- RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RC48-ADC in Combination with gemcitabine CI brief — competitive landscape report
- RC48-ADC in Combination with gemcitabine updates RSS · CI watch RSS
- RemeGen Co., Ltd. portfolio CI